Chronic lymphocytic leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BTK 26
• CD19 33
• BCL-2 10
• TP53 3
• CD20 10
• CD22 6
• ABL1 2
• PI3K 1
• NOTCH1 0
• CXCR4 0
• STAT3 0
• CD123 1
• CD38 1
• HMGB1 0
• PD-1 0
• PD-L1 0
• EGFR 0
• HDAC 0
• MDM2 0
• PPAR 0
• TIM-3 0
• AKT 0
• ALK 0
• ATM 0
• BCMA 1
• BDNF 0
• BRAF 0
• BRD4 0
• CD30 0
• CD47 0
• CSF1R 1
• CTNNB1 0
• ERK 0
• FAK 0
• FLT3 0
• IDH 0
• IL-23 0
• IL-4 0
• KMT2A 0
• MAPK 0
• MMP-9 0
• NLRP3 0
• NRAS 0
• PCSK9 0
• PRMT5 0
• TLR4 0
• VEGF 0

24 of 35+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, United States· US$390,447 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Rationally directed therapy for CLL

  University of Tx Md Anderson Can Ctr· Houston, United States· US$690,011 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Integrating AI and Deep Mutational Scanning to Predict the Cancer-Promoting Effect of Shelterin Mutations

  University of California Berkeley· Berkeley, United States· US$2,197,943 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · R41

  Development of MCL 1-Targeting Antibody–Drug Conjugates for Cancer Therapy

  Immunogenic Cancer Engineering Therapeutics Llc· Englewood Cliffs, United States· US$412,351 awarded in fiscal year 2026· until Aug 2027

• NIH NEI · R01

  Discovery of novel trifunctional hybrid compounds (TFHCs): potential glaucoma therapy with superior IOP reduction and neuroprotection

  Creighton University· Omaha, United States· US$576,730 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Signaling and Powering Anti-cancer Responses in T Cells SPARC

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €2,500,000· until Oct 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Immuno-Modulatory Platform for Advanced CLL Therapy (IMPACT)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €150,000· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias (LeukemiaBlock)

  Masarykova univerzita· Brno, Czechia· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A single-cell-based solution for an early diagnosis of Richter transformation in patients with chronic lymphocytic leukemia (earlyRTdx)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €150,000· until Oct 2027

10 of 143 running projects, newest first. Listed amounts together: US$97.4m + €16.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· BeOne Medicines· Updated 14 Jul 2026

  “This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

  NCT04477291· Aptose Biosciences Inc.· Updated 7 Mar 2025

  “Change in corporate strategy”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· BeOne Medicines· Source

• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· BeOne Medicines· Source

• Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT05479994· BeiGene· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 2
• Flow Cytometry 21
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 9
• Magnetic Resonance Imaging 4
• Machine Learning 10
• Cohort Studies 18
• Genome-Wide Association Study 2

• Sequential versus Simultaneous Quantitative Analysis of Biomarkers in Individual Cells by ICP-MS and Mass Cytometry: A Focus on Immunotherapy.

  Anal Chem, Nov 2025

• Fludarabine metabolism by cytosolic 5'-nucleotidase III and its tissue-specific localization mapping using mass spectrometry imaging.

  Drug Metab Dispos, Oct 2025

See which targets of this disease your abstract mentions, and go to the people working on them.